๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Tianjin
Clinical trial register · China

Clinical Trials in Tianjin, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Institute of Hematology & Blood Diseases Hospital, China203 Tianjin Medical University Cancer Institute and Hospital170 Tianjin Medical University Second Hospital25 Tianjin Medical University25 Tianjin Medical University General Hospital17
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Tianjin

940 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Study of Brenipatide in Adult Participants With Schizophrenia
NCT07410507Schizophrenia
DrugBrenipatide
Eli Lilly and Company
Phase 2
450
Changsha, Chengdu, Hangzhou, Suzhou, Tianjin, Wuhu, Xi'an, Zhumadian
2026-02-10
Recruiting
Blood Pressure Monitor (TH-75) Atrial Fibrillation Detection Function Clinical Trial
NCT07442175Atrial Fibrillation (AF)
Andon Health Co., Ltd
Observational
392
Tianjin
2026-02-09
Recruiting
CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL
NCT07397832Diffuse Large B-Cell Lymphoma (DLBCL)
DrugsPolatuzumab Vedotin·Chidamide·Rituximab
Tianjin Medical University Cancer Institute and Hospital
Phase 2
58
Tianjin
2026-02-03
Not yet open
Iparomlimab and Tuvonralimab Injection Combined With GemOX and Lenvatinib as Conversion Therapy for Initially Potentially Resectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer
NCT07263360BTC
Tianjin Medical University Cancer Institute and Hospital
Phase 2
29
Tianjin
2026-02-01
Recruiting
A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy
NCT07548060NSCLC Stage IV, EGFR Gene Mutation
DrugSacituzumab tirumotecan
Tianjin Medical University Cancer Institute and Hospital
Phase 2
25
Tianjin
2026-02-01
Recruiting
A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer
NCT07358676Small Cell Lung Cancer (SCLC), SCLC, Extensive Stage
Tianjin Medical University Cancer Institute and Hospital
Phase 2
25
Tianjin
2026-02-01
Recruiting
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
NCT07288177Non-small Cell Lung Cancer (NSCLC)
DrugRina-S
Genmab
Phase 2
240
Shanghai, Beijing, Tianjin, Zhangjiakou, Zhengzhou
2026-01-30
Not yet open
A Study of CD19 UCAR-T Cells in Subjects With Autoimmune Diseases
NCT07212322Systemic Lupus Erythematosus, Idiopahic Inflammatory Myopathies, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Sjรถgren's Syndrome
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
24
Tianjin
2026-01-30
Recruiting
Exploratory Study of LP-98 for Injection in ART-Naive HIV-Infected Individuals
NCT07433387HIV
Shanxi Kangbao Biological Product Co., Ltd.
Phase 1/2
30
Tianjin
2026-01-29
Recruiting
Evaluate the Efficacy and Safety of HMI-115 in Women With Moderate to Severe Endometriosis-associated Pain
NCT07318688Endometriosis
Hope Medicine (Nanjing) Co., Ltd
Phase 3
540
Beijing, Nanning, Suzhu, Shanghai, Tianjin
2026-01-29
Recruiting
Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
NCT07234019Immune Thrombocytopenia, Treatment
DrugsDaratumumab๏ผˆAnti-CD38 Monoclonal Antibody๏ผ‰·Rituximab
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
160
Tianjin
2026-01-28
Recruiting
A Single-Arm Phase โ…ก Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast Cance
NCT07321015Platinum-sensitive, TNBC, Triple Negative Breast Cancer, BRCA1/2 Mutation or Not
DrugFluzoparib
Tianjin Medical University Cancer Institute and Hospital
Phase 2
72
Tianjin
2026-01-20
Recruiting
Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
NCT07297563Immune Thrombocytopenia, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
160
Tianjin
2026-01-20
Not yet open
Huangjing Yangji Formula Combined With Resistance Training for Sarcopenia
NCT07321535Sarcopenia
Wangjing Hospital, China Academy of Chinese Medical Sciences
Not applicable
106
Beijing, Changsha, Tianjin
2026-01-15
Recruiting
Effects of PFO Closure on Glymphatic Function and Clinical Symptoms in Patients With Migraine
NCT07170176Migraine Disorders, Patent Foramen Ovale, Right-to-Left Shunt, Cardiac
First Affiliated Hospital Xi'an Jiaotong University
Not applicable
150
Luoyang, Tianjin
2026-01-14
Not yet open
A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma๏ผˆLB2505-0001๏ผ‰
NCT07399444Multiple Myeloma (MM)
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1
38
Zhengzhou, Wuhan, Xuzhou, Nanchang, Beijing, Tianjin
2026-01-10
Recruiting
Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children
NCT07318831Neuroblastoma (NB), Neuroblastoma in Children
DrugChidamide
Tianjin Medical University Cancer Institute and Hospital
Phase 2
27
Tianjin
2026-01-06
Recruiting
Effect of Oliceridine Patient-Controlled Intravenous Analgesia on Postoperative Chronic Pain After Video-Assisted Thoracoscopic Lung Resection
NCT07018375Chronic Postsurgical Pain
DrugsOliceridine·Sufentanil
Tianjin Medical University General Hospital
Phase 4
320
Baoding, Tangshan, Tianjin
2026-01-06
Not yet open
Critical Illness After Hematopoietic Cell Transplantation
NCT07328724Critical Illness, Ventilated Patients, Hematopoetic Stem Cell Transplantation, Transplant Complication
Peking University People's Hospital
Observational
4,000
Beijing, Chongqing, Hangzhou, Harbin, Tianjin, Wuhan
2026-01-01
Not yet open
A Study to Investigate the Biomarkers of Hemay005 in Adult Participants With Moderate to Severe COPD
NCT07314242COPD (Chronic Obstructive Pulmonary Disease)
Ganzhou Hemay Pharmaceutical Co., Ltd
Phase 2
120
Tianjin
2026-01-01
Recruiting
Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder
NCT07420296Neuromyelitis Optica Spectrum Disorders (NMOSD)
Tianjin Medical University General Hospital
Phase 3
198
Tianjin
2026-01-01
Recruiting
Hippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain Metastases in EGFR-Mutated Lung Cancer
NCT07505173Naive Advanced Non-small Cell Lung Cancer With EGFR-sensitive Mutations (EGFR Exon 19 Deletion and Exon 21 L858R Mutation) and Symptomatic Brain Metastases
Tianjin Medical University Cancer Institute and Hospital
Phase 2
74
Tianjin
2026-01-01
Recruiting
CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases
NCT07315087SLE - Systemic Lupus Erythematosus, SSc-Systemic Sclerosis, IIM- Idiopathic Inflammatory Myopathies, ANCA Associated Vasculitis (AAV)
DrugQT-019C
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
12
Tianjin
2026-01-01
Recruiting
Development and Application of an AI Chatbot for Perioperative Health Education in Thyroid Cancer Patients
NCT07634978Thyroid Cancer
Tianjin Medical University Cancer Institute and Hospital
Not applicable
150
Tianjin
2026-01-01
Active, closed
Multimodal Prediction of Postoperative Prognosis After Partial Nephrectomy for Endophytic Renal Cell Carcinoma
NCT07697417Renal Cell Carcinoma, Kidney Neoplasms, Endophytic Renal Tumor, Postoperative Renal Function
Tianjin Medical University Second Hospital
Observational
406
Tianjin
2026-01-01
Not yet open
Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study
NCT07365410Non-small Cell Lung Cancer (NSCLC), Brain Metastases, Furmonertinib, EGFR Mutation
DrugsFurmonertinib·Pemetrexed·Carboplatin
Tianjin Medical University Cancer Institute and Hospital
Phase 2
60
Tianjin
2026-01
Recruiting
Investigation on Suicide Risk Factors of Patients With Mood Disorders
NCT07523490Mood Disorders, Suicide
Tianjin Anding Hospital
Observational
300
Tianjin
2025-12-31
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
NCT07221357Untreated, Unresectable, or Metastatic Colorectal Cancer
DrugsFolfiri·Capox·Folfox·Pumitamig
Bristol-Myers Squibb
Phase 2/3
990
Hefei, Chongqing, Fuzhou, Fuzhou Fujian, Guangzhou, Shenzhen, Nanning, Tianjin
2025-12-31
Not yet open
A Multicenter Real-World Study on TKI Therapy After Progression on First-Line TKI/IO Therapy or TKI/IO Therapy After Progression on First-Line TKI in Chinese Patients With Metastatic Renal Cell Carcinoma (mRCC)
NCT07324876RCC
Tianjin Medical University Cancer Institute and Hospital
Observational
860
Tianjin
2025-12-31
Not yet open
A Phase II Clinical Study of Zanubrutinib Combined With Four Cycles of CD20 Monoclonal Antibody and Reduced-Dose Bendamustine in the Treatment of Untreated Waldenstrรถm Macroglobulinemia
NCT07259122Waldenstrรถm Macroglobulinemia (WM)
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
43
Tianjin
2025-12-30
By invitation
Unrelated Umbilical Cord Blood Transplantation for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
NCT07539662ALS (Amyotrophic Lateral Sclerosis)
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
8
Tianjin
2025-12-29
Recruiting
Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular Lymphoma
NCT07299149Follicular Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
34
Tianjin
2025-12-25
Recruiting
Neoadjuvant Chemotherapy Combined With Finotonlimab in the Treatment of Locally Advanced Hypopharyngeal Carcinoma
NCT07248956Hypopharyngeal Carcinoma
Eye & ENT Hospital of Fudan University
Phase 2
116
Harbin, Jinan, Beijing, Shanghai, Tianjin
2025-12-22
Recruiting
Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases
NCT07304739Non Small Cell Lung Cancer
DrugFurmonertinib
Tianjin Medical University Cancer Institute and Hospital
Phase 2
30
Cangzhou, Tianjin
2025-12-22
Not yet open
Efficacy and Safety of Anrikefon Injection for the Treatment of Postoperative Pain in Patients Undergoing Totally Laparoscopic Radical Distal Gastrectomy
NCT07330063Gastrectomy
Tianjin Medical University Cancer Institute and Hospital
Phase 2
114
Tianjin
2025-12-22
Recruiting
Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma
NCT07261163Mantle Cell Lymphoma
DrugsZanubrutinib·Obinutuzumab·Lenalidomide
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
37
Tianjin
2025-12-20
Recruiting
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT07225946Prostatic Neoplasms, Castration-Resistant
DrugsPasritamig·Prednisone/Prednisolone·Paclitaxel
Janssen Research & Development, LLC
Phase 3
800
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Nanjing, Shanghai, Tianjin
2025-12-19
Recruiting
A Clinical Study Evaluating the Safety and Efficacy of GT729 Universal Cell Injection in the Treatment of Refractory or Relapsed Chronic Graft-versus-host Disease (cGVHD)
NCT07253259cGVHD
Grit Biotechnology
Phase EARLY_PHASE1
36
Tianjin
2025-12-18
Recruiting
A Cohort Study on the Association Between the ANS Function and Acute GvHD
NCT07374874Transplant-Related Disorder
Institute of Hematology & Blood Diseases Hospital, China
Observational
60
Tianjin
2025-12-18
Recruiting
PET Myocardial Fatty-acid Metabolic Imaging With XTR003 Injection and 18F-FDG to Assess Myocardial Viability in Ischemic Cardiomyopathy
NCT07443696Ischemic Cardiomyopathy, Heart Failure
Sinotau Pharmaceutical Group
Phase 2
40
Beijing, Tianjin
2025-12-18
Not yet open
Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer
NCT07246317Breast Cancer
DrugsPertuzumab·Iparomlimab and Tuvonralimab·Trastuzumab·Carboplatin
Tianjin Medical University Cancer Institute and Hospital
Phase 2
188
Guangzhou, Shijiazhuang, Luoyang, Nanyang, Chengdu, Tianjin, Jiaxing
2025-12-15
Recruiting
Near-infrared Light Therapy Device for Mild-Moderate Alzheimer's Disease (NirsCure-03A)
NCT07262645Alzheimer s Disease
Danyang Huichuang Medical Equipment Co., Ltd.
Phase 3
320
Beijing, Shijiazhuang, Baotou, Suzhou, Xi'an, Shanghai, Taiyuan, Tianjin
2025-12-15
Recruiting
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
NCT07222267Breast Cancer, Advanced Solid Tumor
DrugBG-75202
BeOne Medicines
Phase 1
86
Beijing, Chongqing, Xiamen, Guangzhou, Harbin, Nanjing, Shanghai, Tianjin
2025-12-11
Recruiting
A Real-World Study of Guselkumab in Chinese Participants With Ulcerative Colitis
NCT07302360Colitis, Ulcerative
Xian-Janssen Pharmaceutical Ltd.
Observational
200
Beijing, Changzhou, Guangzhou, Hangzhou, Nanjing, Shijiazhuang, Tianjin
2025-12-11
Not yet open
The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic Anemia
NCT07287228Aplastic Anemia, Refractory, Relapse
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
37
Tianjin
2025-12-10
Active, closed
Prognostic Model of Elderly Hodgkin Lymphoma in China
NCT07374068Hodgkin Lymphoma
Tianjin Medical University Cancer Institute and Hospital
Observational
400
Tianjin
2025-12-09
Recruiting
A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer
NCT07230106Prostate Cancer
DrugsHS-20093·Zeprumetostat·Abiraterone·Enzalutamide
Jiangsu HengRui Medicine Co., Ltd.
Phase 2
218
Nanjing, Tianjin
2025-12-08
Active, closed
A Clinical Study to Evaluate GK01 Cell Injection in Combination With PD-1 Monoclonal Antibody for Advanced Solid Tumors
NCT07407985Solid Tumors
Tianjin Medical University Cancer Institute and Hospital
Phase 1
15
Tianjin
2025-12-04
Recruiting
Serplulimab for Locally Advanced Cervical Cancer
NCT07340489Cervical Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2
216
Tianjin
2025-12-03
Recruiting
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
NCT06937229Alzheimer Disease, Agitation
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
650
Beijing, Haidian District, Guangzhou, Shenzhen, Changsha, Nanjing, Tianjin, Hangzhou
2025-12-02
Recruiting
A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors
NCT07229586Solid Tumor
DrugsGemcitabine Hydrochloride·Adebrelimab·Paclitaxel
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1/2
100
Tianjin
2025-12-02
Recruiting
Using Mobile Technology-assisted Outpatient Maintenance Therapy Pediatric ALL
NCT07278882Pediatric Acute Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
100
Tianjin
2025-12-01
Recruiting
WAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC
NCT07330050NSCLC (Non-small Cell Lung Cancer)
DrugPaclitaxel
Tianjin Medical University Cancer Institute and Hospital
Phase 2
31
Tianjin
2025-12-01
Recruiting
TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemoimmunotherapy
NCT07330037NSCLC
DrugTislelizumab
Tianjin Medical University Cancer Institute and Hospital
Phase 2
41
Tianjin
2025-12-01
Not yet open
Sac-TMT Plus Bevacizumab as Second-Line Treatment for Advanced Non-Squamous Non-Small Cell Lung Cancer
NCT07244926Lung Cancer
DrugsSacituzumab tirumotecan·Bevacizumab
Tianjin Medical University Cancer Institute and Hospital
Phase 2
31
Tianjin
2025-12
Not yet open
A Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell Neoplasms
NCT07234045Relapsed/Refractory B-cell Non-Hodgkin Lymphoma, Relapsed/Refractory B-cell ALL
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
30
Tianjin
2025-11-30
Recruiting
Electroacupuncture Combined With PD-1 Inhibitor for ECOG2 Advanced NSCLC
NCT07239661Non-Small Cell Lung Cancer, Electroacupuncture, PD-1 Inhibitors, ECOG PS 2 Points
Kong Fanming
Not applicable
120
Tianjin
2025-11-30
Recruiting
Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma
NCT07259070DLBCL, CLL, FL, MCL
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
20
Tianjin
2025-11-29
Recruiting
Safety Trial of 68Ga/177Lu-NRT6020 in FAP-Positive Advanced Solid Tumor Patients
NCT06911489Solid Tumor Malignancy
DrugPCV20
Chengdu New Radiomedicine Technology Co. LTD.
Phase 1
132
Shanghai, Tianjin
2025-11-29
Recruiting
Study of CM512 Injection in Subjects With Chronic Spontaneous Urticaria(CSU)
NCT07166211Chronic Spontaneous Urticaria (CSU)
DrugCM512
Keymed Biosciences Co.Ltd
Phase 2
48
Tianjin
2025-11-27
Recruiting
A Phase II Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of SR604 Injection in Patients With Von Willebrand Disease
NCT07640893Von Willebrand Disease (VWD)
DrugSR604
Shanghai RAAS Blood Products Co., Ltd.
Phase 2
24
Changsha, Hefei, Jinan, Nanning, Suzhou, Taiyuan, Tangshan, Tianjin
2025-11-26
Recruiting
Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer
NCT07233252Renal Pelvic Carcinoma, Tislelizumab, PD-1 Inhibitor, Kidney-sparing
DrugsNab-paclitaxel·Tislelizumab
Tianjin Medical University Second Hospital
Phase 2
35
Tianjin
2025-11-25
Recruiting
A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)
NCT07286175Bipolar Disorder
DrugBrenipatide
Eli Lilly and Company
Phase 2
400
Changsha, Hangzhou, Huzhou, Jinan, Shanghai, Shijiazhuang, Tianjin, Xiamen
2025-11-24
Not yet open
Subthalamic Nucleus Versus Globus Pallidal Internus Deep Brain Stimulation for Parkinson Disease
NCT07250685PD - Parkinson's Disease
Zhang Jianguo
Not applicable
86
Beijing, Wuhan, Nanjing, Dalian, Jinan, Shanghai, Tianjin, Hangzhou
2025-11-24
Recruiting
Specialist Nurse-Led Nursing Management for Patients Undergoing Head and Neck Cancer Surgery
NCT07622381Head & Neck Cancer
Tianjin Medical University Cancer Institute and Hospital
Not applicable
80
Tianjin
2025-11-24
Recruiting
A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia
NCT07175493Autoimmune Cytopenia, Immune Thrombocytopenia (ITP), Autoimmune Hemolytic Anemia, Evans Syndrome
Keymed Biosciences Co.Ltd
Phase 1/2
158
Zhengzhou, Changzhi, Tianjin
2025-11-18
Recruiting
A Study on Predicting the Risk of Distant Metastasis in Breast Cancer Using AI-Generated Spatial Pathological Maps
NCT07244094Breast Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
400
Changchun, Tianjin, Hangzhou
2025-11-15
Recruiting
Comparison of Diagnostic Accuracy Between XTR004 PET MPI and the Composite Index of Quantitative Coronary Angiography (QCA) and Fractional Flow Reserve (FFR)
NCT07439133Coronary Artery Disease(CAD)
Sinotau Pharmaceutical Group
Phase 3
395
Beijing, Foshan, Tianjin
2025-11-14
Recruiting
Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
NCT07109219B-cell Acute Lymphoblastic Leukemia (B-ALL)
AstraZeneca
Phase 1/2
83
Guangzhou, Tianjin
2025-11-12
Recruiting
A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer
NCT07361003Refractory Metastatic Colorectal Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 3
464
Fuzhou, Harbin, Nanjing, Jinan, Tianjin, Hangzhou
2025-11-12
Recruiting
A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT07138209Relapsed or Refractory Multiple Myeloma
DrugsQLS32015·Selinexor·Pomalidomide·Dexamethasone
Qilu Pharmaceutical Co., Ltd.
Phase 3
228
Tianjin
2025-11-07
Recruiting
A Phase I Study of SIM0609 in Adult Participants With Locally Advanced/Metastatic Solid Tumors
NCT07265921Advanced Solid Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
232
Beijing, Nanjing, Shanghai, Tianjin, Wuhan
2025-11-07
Recruiting
A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer
NCT07198633Advanced Prostate Cancer
DrugsQLC5508·Abiraterone acetate·Enzalutamide
Qilu Pharmaceutical Co., Ltd.
Phase 1/2
212
Tianjin
2025-11-05
Recruiting
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis
NCT07121413Idiopathic Pulmonary Fibrosis(IPF)
DrugSV001
Shanghai Synvida Biotechnology Co.,Ltd.
Phase 2
48
Chengdu, Guangzhou, Hangzhou, Nanchang, Nanjing, Neimeng, Shanghai, Tianjin
2025-11-04
Recruiting
DCRT vs. Surgery in Resectable ESCC Patient Achiving cCR/PR After nCI
NCT07162506Esophageal Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2
120
Tianjin
2025-11-03
Recruiting
Liposomal Irinotecan, Capecitabine and Enlonstobart With Short-Course Radiotherapy for Locally Advanced Rectal Cancer
NCT07281157Advanced Rectal Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2
30
Tianjin
2025-11-01
Recruiting
[18F]NIDF PET Imaging in Tau-related Diseases
NCT07306598Neurodegenerative Disease, Alzheimer s Disease, Tauopathies
Tianjin Medical University
Observational
20
Hefei, Qingdao, Tianjin
2025-11-01
Not yet open
Dexmedetomidine-Esketamine Combination for Sedation and Analgesia in ICU Patients
NCT06468436Aged, Intensive Care Units, Ventilators, Mechanical, Dexmedetomidine
DrugMidazolam
Peking University First Hospital
Not applicable
1,508
Beijing, Tianjin
2025-11
Not yet open
Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer
NCT07172412Extensive Stage Lung Small Cell Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2
165
Tianjin
2025-11
Not yet open
A Phase III Study of NTQ5082 Capsules in the Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients
NCT07177859Paroxysmal Nocturnal Hemoglobinuria
DrugsNTQ5082·Eculizumab
Nanjing Chia-tai Tianqing Pharmaceutical
Phase 3
78
Tianjin
2025-11
Recruiting
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
NCT07223593Peripheral Arterial Disease
DrugOrforglipron
Eli Lilly and Company
Phase 3
1,205
Beijing, Chengdu, Guangzhou, Harbin, Luoyang Shi, Nanjing, Shanghai, Tianjin
2025-10-31
Recruiting
A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.
NCT07219615Chronic Spontaneous Urticaria
DrugRitlecitinib
Pfizer
Phase 2
200
Beijing, Guangzhou, Shijiazhuang, Shanghai, Tianjin, Hangzhou
2025-10-30
Not yet open
A Clinical Study to Explore CT1194D in Patients With Relapsed/Refractory B-Cell Neoplasms
NCT07200479Relapsed/Refractory B-Cell Neoplasms
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
20
Tianjin
2025-10-30
Active, closed
ClinicAL outComes of IntraVascular Lithotripsy Combined With Conventional Lesion Preparation in Patients With Moderate to Severe Coronary Artery Calcification
NCT07340294Coronary Artery Calcification, Calcific Coronary Arteriosclerosis
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
1,096
Nanchang, Shenyang, Hangzhou, Tianjin
2025-10-24
Recruiting
Surgical Total Clearance Versus Extrahepatic Bile Duct Preservation for Biliary Tract Malignancies: A Single-Center, Randomized, Two-Arm, Prospective Phase II Clinical Trial
NCT07609641BTC
Tianjin Medical University Cancer Institute and Hospital
Not applicable
60
Tianjin
2025-10-20
Recruiting
Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML
NCT06611839AML, IDH1 Mutation, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
23
Tianjin
2025-10-17
Recruiting
A Single-arm, Open-label Study of GK01 in Combination With or Without Chemotherapy for the Adjuvant Treatment of Solid Tumors
NCT07351903Solid Tumors
DrugGK01
Tianjin Medical University Cancer Institute and Hospital
Phase 1
15
Tianjin
2025-10-16
Recruiting
A Study of HRS-2329 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications
NCT07189949Advanced Solid Tumors Harboring RAS Mutations or Amplifications
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
120
Tianjin
2025-10-16
Recruiting
A Study to Assess Safety, Tolerability and Drug Levels of Navlimetostat (BMS-986504) in Participants With Advanced Solid Tumors
NCT07077434Advanced Solid Tumors
DrugBMS-986504
Bristol-Myers Squibb
Phase 1
32
Beijing, Fuzhou, Guangzhou, Shenzhen, Harbin, Xinxiang, Jinan, Tianjin
2025-10-15
Recruiting
Aspirin Continuation or Discontinuation in Conservative Treatment for Chronic Subdural Hematoma
NCT07240454Chronic Subdural Hematoma
Tao Liu
Not applicable
143
Beijing, Tianjin
2025-10-15
Recruiting
A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD)
NCT07129343Von Willebrand Disease (VWD)
DrugAdvate
Takeda
Phase 3
20
Beijing, Guangzhou, Jihan, Shanghai, Suzhou, Tianjin, Wuhan
2025-10-13
Recruiting
Brain Cognitive Network Abnormalities in Anemia Patients Using fNIRS
NCT07578675Aplastic Anemia, Myelodysplastic Syndromes, Autoimmune Hemolytic Anemia, Functional Near-Infrared Spectroscopy
Institute of Hematology & Blood Diseases Hospital, China
Observational
323
Tianjin
2025-10-11
Recruiting
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
NCT07140913Mania, Bipolar Disorder
DrugKarXT
Bristol-Myers Squibb
Phase 3
424
Beijing, Guangzhou, Baoding, Shijiazhuang, Nanjing, Xi'an, Chengdu, Tianjin
2025-10-08
Recruiting
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
NCT07100106Breast Cancer
DrugsGiredestrant·Abemaciclib
Genentech, Inc.
Phase 1/2
285
Jinan, Shanghai, Tianjin, Nanning
2025-10-07
Recruiting
Safety and Efficacy of Umbilical Cord Blood-Derived Mesenchymal Stem Cells in the Treatment of Long-Term Cytopenia After CAR-T Therapy
NCT07212335Immune Effector Cell Associated Hematotoxicity
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1
15
Tianjin
2025-10-01
Recruiting
Tislelizumab Combined With Chemotherapy for Different Cycles of Neoadjuvant Therapy for Locally Advanced Resectable Squamous Cell Carcinoma of the Head and Neck (NeoTempo)
NCT07147426Head &Amp; Neck Squamous Cell Carcinoma
DrugTislelizumab
Tianjin Medical University Cancer Institute and Hospital
Phase 2
100
Tianjin
2025-10-01
Recruiting
Preliminary Trial of SNA014 for Pancreatic Cancer
NCT07597772Pancreatic Cancer
Drug68Ga-NODAGA-SNA006
SmartNuclide Biopharma
Phase EARLY_PHASE1
12
Tianjin
2025-10-01
Not yet open
Chemotherapy Combined With Targeted Therapy as First-line Treatment for Mantle Cell Lymphoma Based on MRD and PET-CT Assessment
NCT07206264Mantle Cell Lymphoma
DrugBendamustine
Tianjin Medical University Cancer Institute and Hospital
Phase 2
45
Fuzhou, Shijiazhuang, Harbin, Jinan, Tianjin
2025-10
Not yet open
A Phase 3 Study of HS-20094 in Patients With T2DM
NCT07156539Type 2 Diabetes
DrugDulaglutide
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 3
546
Jinan, Tianjin
2025-09-30
Recruiting
A Real-world Prospective Observational Study on the Efficacy and Safety of L-AmB(Liposomal Amphotericin B) for br- IFD(Breakthrough Invasive Fungal Disease) in Children and Adolescent Patients With Hematological Malignancies Receiving Triazoles or Echinocandins Prophylaxis
NCT07357038Fungal Disease
Institute of Hematology & Blood Diseases Hospital, China
Observational
38
Tianjin
2025-09-30
Rows per page Showing 201–300 of 940
Previous 1 2 3 4 5 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/tianjin?page=3

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 940 of those studies with a site in Tianjin.

How many clinical trials are recruiting in Tianjin?

601 of the 940 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 153 have not yet opened recruitment, 162 are active but closed to new participants, and 24 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.